Furthermore, Deferoxamine has shown potential in reducing NLRP3 activation through the ROS/NF-κB pathway, influencing microglial polarization, decreasing neutrophil and macrophage infiltration, and inhibiting the release of inflammatory factors following traumatic brain injury. Here, NFKB1 is linked to injury.